



DIRECT PURCHASE PROGRAM

FOR PATIENTS

Effective and Affordable Osteoarthritis (OA)
Knee Pain Relief That Keeps Your Patients Moving

The OrthogenRx Direct Purchase Program provides a convenient solution to underinsured patients. Patients can access and benefit from TriVisc by purchasing the medication directly through our pharmacy partner. **See reverse for participation details.**

trivisc.com

TriVisc[®]
● ● ●

3 injection hyaluronic acid regimen



The OrthogenRx Direct Purchase Program provides a convenient solution to underinsured patients.

Patients can access and benefit from TriVisc by purchasing the medication directly through our pharmacy partner.

To Participate in the OrthogenRx Direct Purchase Program:

- 1 Provider submits benefit investigation request to OrthogenRx Reimbursement Navigator at orthogenrx.aspnprograms.com
- 2 Benefit investigation confirms patient eligibility.
- 3 OrthogenRx Reimbursement Navigator provides Direct Purchase Program information form to the provider.
- 4 Provider communicates TriVisc purchase option to patient and then advises OrthogenRx Reimbursement Navigator team to initiate Direct Purchase Program.
- 5 OrthogenRx Reimbursement Navigator team contacts patient to collect payment; then notifies and ships TriVisc directly to provider's office.

To learn more contact the OrthogenRx Reimbursement Navigator at **1-866-556-2259**

orthogenRx
Reimbursement Navigator

Program Eligibility

Patient must have no insurance or commercial insurance and a benefit investigation result that has a designation of "no coverage," "non-preferred," or "category block."

- Patient must be 18 years of age or older.
- Patient must be a resident of the United States or U.S. Territories.
- Patient must have a valid prescription.
- Patients participating in any federal or state health care program, including without limitation Medicare, Medicaid, the Department of Veterans Affairs healthcare program, TRICARE, and any federal or state employee benefit program are not eligible for the Program.

Summary of Indications for Use: TriVisc is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. Full prescribing information can be found in product labeling, at trivisc.com.

Adant is a registered trademark of Meiji Pharma Spain.
TriVisc is a registered trademark of OrthogenRx, Inc. ORTHEN-CPFRM-020120

TriVisc
3 injection hyaluronic acid regimen

orthogenRx
multi-regimen hyaluronic acids

Distributed by:
OrthogenRx, Inc
Doylestown Commerce Center
2005 S. Easton Road, Suite 207
Doylestown, PA 18901
1-844-436-8472

Manufactured by:
Meiji Pharma Spain, S.A.
Avda. De Madrid 94.
28802 Alcalá de Henares
(Madrid), Spain